Clinical Trial Update: Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a combination of NAs and Peg IFN α-2b for hepatitis B-related compensatory cirrhosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis of Liver Due to Hepatitis

Drugs mentioned

• NAs
• PEG-IFN-α-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Cirrhosis of Liver Due to Hepatitis B (Disorder) | Phase 2 | Status: UNKNOWN